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https://doi.org/10.1016/j.stemcr.2018.10.012SUMMARYWe generated patient-specific disease-free induced pluripotent stem cells (iPSCs) from peripheral blood CD34+ cells and differentiated
them into functional endothelial cells (ECs) secreting factor VIII (FVIII) for gene and cell therapy approaches to cure hemophilia A
(HA), an X-linked bleeding disorder caused by F8 mutations. iPSCs were transduced with a lentiviral vector carrying FVIII transgene
driven by an endothelial-specific promoter (VEC) and differentiated into bona fide ECs using an optimized protocol. FVIII-expressing
ECs were intraportally transplanted in monocrotaline-conditioned non-obese diabetic (NOD) severe combined immune-deficient
(scid)-IL2rg null HA mice generating a chimeric liver with functional human ECs. Transplanted cells engrafted and proliferated in the
liver along sinusoids, in the long term showed stable therapeutic FVIII activity (6%). These results demonstrate that the hemophilic
phenotype can be rescued by transplantation of ECs derived fromHA FVIII-corrected iPSCs, confirming the feasibility of cell-reprogram-
ming strategy in patient-derived cells as an approach for HA gene and cell therapy.INTRODUCTION
Hemophilia A (HA) is a rare recessive X-linked bleeding dis-
order and is caused bymutations and/or deletions in the F8
gene, encoding the coagulation factor VIII (FVIII) (Bolton-
Maggs and Pasi, 2003; Graw et al., 2005). On the basis of
FVIII plasma activity, three forms of HA are recognized: se-
vere (<1%), moderate (1%–5%), and mild (5%–40%) (Bol-
ton-Maggs and Pasi, 2003). The current therapy consists
of a repetitive infusion of recombinant or plasma-derived
FVIII. This replacement therapy, however, does not repre-
sent a definitive cure and, moreover, 20%–40% of the
treated patients develop anti-FVIII neutralizing antibodies
(Den Uijl et al., 2011). Several alternatives are proposed,
such as the drug emicizumab, a prophylactic therapy for
adult and pediatric patients (Lenting et al., 2017; Shima
et al., 2016), and some approaches of gene and cell therapy.
Indeed, in HA patients the restoration of FVIII activity
above 2%–5% could ameliorate the patients’ quality of
life. Gene transfer approaches for hemophilic patients
have been running for almost 20 years (Nathwani et al.,
2017). Presently, adeno-associated viruses (AAVs) are usedStem Cell Reports
This is an open access article under the Cfor hemophilia gene therapy due to their relative safety,
simplicity, and high liver tropism (Naso et al., 2017) but,
despite remarkable results obtained with HB (Nathwani
et al., 2011) and HA (Rangarajan et al., 2017), pre-existing
immunity to AAVs and their long-term efficacy in young
patients are still a concern. Several approaches for hemo-
philia gene therapy using lentiviral vectors (LVs) were
developed and tested in preclinical models showing prom-
ising results (Cantore et al., 2015; Merlin et al., 2017).
Nevertheless, a combined approach of gene and cell ther-
apy deserves further consideration to develop a safe cell-
based treatment.
Previous studies have demonstrated that transplanted
liver sinusoidal endothelial cells (LSECs) from a healthy
donor can correct the bleeding phenotype of HAmice (Fol-
lenzi et al., 2008; Yadav et al., 2012), and indeed LSECs are
recognized as key FVIII producers (Fomin et al., 2013; Sha-
hani et al., 2014; Zanolini et al., 2015). Recent data have
proven that FVIII expression under an endothelial specific
promoter using LV, is able to induce immunotolerance to
FVIII and correct the bleeding phenotype of the disease
(Merlin et al., 2017). In addition, successful transplantationj Vol. 11 j 1391–1406 j December 11, 2018 j ª 2018 The Authors. 1391
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of human LSECs isolated from adult liver has recently been
reported (Filali et al., 2013; Fomin et al., 2013). Accord-
ingly, HA cell therapy must rely on LSECs or immature
endothelial progenitors as sources of transplantable cells,
which are not always readily available. As such, other
stem cell (SC) and progenitor cell populations have been
evaluated either for their potential for in vivo FVIII produc-
tion, or as carrier cells engineered for ectopic FVIII expres-
sion (Harb et al., 2009; Wang et al., 2012a, 2012b).
The discovery of induced pluripotent stem cells (iPSCs)
has revolutionized regenerative medicine due to their po-
tential for self-renewal, growth, and differentiation capac-
ity. In particular, reprogramming of genetically corrected
somatic cells can be used to generate autologous, disease-
free iPSCs, which can be then differentiated into progeni-
tor cells relevant for gene and cell therapy applications,
e.g., endothelial cells (ECs) (Garcon et al., 2013; Raya
et al., 2009; Wang et al., 2012c). iPSCs can be generated
starting from several cell types, including fibroblasts (Taka-
hashi et al., 2007), peripheral blood (PB) mononuclear cells
(MNC), mobilized CD34+ cells from PB (Loh et al., 2009)
and, interestingly, from non-mobilized cells enriched
from small volumes of PB (Merling et al., 2013).
In the present study, we generated iPSCs from PB CD34+
cells of healthy donors and hemophilic patients, using two
polycistronic, LoxP-flanked LVs expressing OCT4, SOX2,
and KLF4 with or without miRNAs 302/367 cluster to
enhance the reprogramming efficiency (Barroso-del Jesus
et al., 2009).
The iPSCs were subsequently differentiated into func-
tional ECs according to a newly optimized differentiation
protocol and were corrected by gene transfer using a LV.
Upon injection into a mouse model of HA, the FVIII-ex-
pressing HA-iPSC-derived ECs were able to produce and
secrete functional FVIII, restoring therapeutic levels of
FVIII activity.RESULTS
Generation of iPSCs from Fibroblasts and CD34+ Cells
from Cord Blood
To generate iPSCs we used two floxable LVs at MOI = 5, one
expressing OCT4, SOX2, and KLF4 (LV.SFFV.OSK; Fig-
ure S1A) from a single cistron, and another expressing
the same reprogramming cassette together with the
human miR302/367 cluster (LV.SFFV.OSK.miR302/367,
Figure S1B). We obtained good quality iPSCs by reprogram-
ming both patient skin fibroblasts and CD34+ cells from
cord blood (CB) of healthy donors (Figure S2). iPSC col-
onies from the reprogrammed fibroblasts appeared after
2 months (Table S1). Obtained iPSCs showed ESC-like
morphology (Figure S2A), were positive for alkaline phos-1392 Stem Cell Reports j Vol. 11 j 1391–1406 j December 11, 2018phatase (AP) (Figure S2B) and expressed the endogenous
factors (Figure S2C), while the exogenous factors were
silenced (Figure S2D). Immunofluorescence (IF) showed
the expression of stem cell markers (OCT4, SOX2, TRA1-
81, and SSEA-4; Figure S2E), and NANOG promoter anal-
ysis demonstrated that 40% of CpG analyzed were unme-
thylated (Figure S2F). In parallel, we generated iPSCs from
CB-derived CD34+ cells, colonies appeared after 20 days
and we obtained over 20 bona fide iPSC clones (Figures
S3A–S3E). Compared with fibroblasts, CD34+ cells from
PB are easier to collect, because the blood can be recovered
during routine blood sample collection, thus avoiding an
invasive risky biopsy procedure for HA patients. On this ba-
sis, we opted to carry out our study using PB CD34+ cells
from healthy donors and HA patients.
Generation of iPSCs from CD34+ Cells of Healthy and
HA Donors
In ten independent experiments (five healthy donors, one
heterozygous control, and four HA patients), we isolated
3.3 ± 1.18 3 105 non-mobilized CD34+ cells from 27.8 ±
11 mL of PB (Table 1). As described previously (Merling
et al., 2013), expanded CD34+ cells were transduced with
both reprogramming LVs atMOI = 5 and colonies appeared
after 20 days. From each LV.SFFV.OSK reprogramming
experiment, we obtained about 20 clones (data not
shown), most of which degenerated over time, while,
from the reprogramming with LV.SFFV.OSK.miR302/367
of healthy and HA CD34+ cells, we obtained 41.8 ± 16
and 18.2 ± 6.5 clones, respectively, which reached
advanced passages in culture. The iPSC colonies were
picked based on ESC-like morphology (Figures 1A and
1C). We established 10–15 clones for each donor (Table
S1). We observed that the highest quality clones from
both healthy and HA iPSC clones, had one to two copies
of integrated LV in the genome, as determined by real-
time PCR analysis (Table S2). All iPSC clones were charac-
terized for pluripotency markers including AP positivity
(Figures 1B and 1D), expression of endogenous (Figures
1E and 1F) and exogenous reprogramming factors (Figures
1G and 1H), and SC markers (OCT4, SOX2, TRA1-81, and
SSEA-4; Figures 1I and 1J). The iPSC clones reached >100
passages (P) and maintained a stable karyotype (Figures
1K and 1L). NANOG promoter methylation profile showed
that 63% of analyzed CpG islands were unmethylated both
in healthy and HA iPSCs. In contrast, in CD34+ cells from
healthy and HA donors 92% and 95% of sites were methyl-
ated, respectively (Figures 1M and 1N).
Moreover, telomere lengths increased between P5 and
P20 (the longest cell passage analyzed), demonstrating a re-
activation of the telomerase complex (Figures 1O and 1P).
Finally, iPSCs were able to generate embryoid bodies
(EBs) which expressed the three germ layers markers
Table 1. List of Hemophilic Patients and Healthy Donors from Whom iPSCs Were Generated
Number of
Isolation Source Donor Mutation
mL of Starting
Peripheral Blood
Number of CD34+
Cells Isolated
Number of
Obtained Colonies
1 peripheral blood healthy none 50 450,000
CD34+
30 iPSC colonies
2 peripheral blood healthy none 25 300,000
CD34+
19 iPSC colonies
3 peripheral blood healthy none 50 600,000
CD34+
40 iPSC colonies
4 peripheral blood healthy none 22 350,000
CD34+
60 iPSC colonies
5 peripheral blood healthy none 21 400,000
CD34+
60 iPSC colonies
6 cord blood healthy none 35 400,000
CD34+
25 iPSC colonies
7 cord blood healthy none 40 500,000
CD34+
35 iPSC colonies
8 peripheral blood heterozygous c.2244C > G,
exon 14
24 250,000
CD34+
22 iPSC colonies
9 peripheral blood severe HA intron 22
inversion
21 200,000
CD34+
6 iPSC colonies
10 peripheral blood severe HA unknown 23 300,000
CD34+
18 iPSC colonies
11 peripheral blood severe HA c.2244C > G,
exon 14
21 300,000
CD34+
20 iPSC colonies
12 peripheral blood severe HA c.6273G > A,
exon 21
21 180,000
CD34+
25 iPSC colonies
13 skin biopsy severe HA c.6273G > A,
exon 21
11 iPSC colonies(NES, NCAM, and OTX2 for ectoderm; ACTA2, TBXT,
and TBX6 for mesoderm; AFP, FOXA2, and SOX17 for
endoderm; Figures 1Q) and could be differentiated into
adipogenic, osteogenic, and chondrogenic cells (Figures
1R–1T). Collectively, these results showed that PB-
CD34+ cells were successfully reprogrammed into iPSCs
expressing SC markers with a good differentiation
potential.
Differentiation of CD34+-iPSCs into ECs
We differentiated CD34+-iPSCs into ECs using two
different protocols, one involving BMP4 and VEGF and
the other VEGF only. During differentiation, EBs acquired
an endothelial-like morphology with both protocols (Fig-
ures 2A and 2B). RT-PCR analyses on ECs obtained from
differentiation at days 10 and 20 showed an increase of
endothelial markers, both early stage, such as KDR and
TEK, and late stage, such as PECAM1 and VEC (Figure 2C).
Noteworthy, ECs differentiated with the BMP4 protocol,expressed endothelial markers in a comparable manner
to human umbilical vein endothelial cells (HUVECs),
which were used as positive control. During the differen-
tiation protocol, healthy EBs showed the acquisition of
the endothelial phenotype that correlate with the gradual
increase of F8 expression (Figure 2C). We further
confirmed endothelial markers expression by flow cytom-
etry analyses on ECs differentiated with BMP4 protocol.
ECs were positive for CD31, VEC, VWF, and KDR, and
were negative for CD45 (Figure 2D). Human blood
outgrowth endothelial cells (BOECs) and fibroblasts were
used as positive and negative controls, respectively (Fig-
ure S4). These findings were corroborated by the fact
that ECs showed a decrease in telomere length when
compared with parental iPSCs (Figure 2E), were heavily
methylated (97%; Figure 2F) and showed a stable karyo-
type (Figure 2G). In conclusion, ECs can be obtained
from CD34+-derived iPSCs with higher efficiency using
the BMP4-inclusive protocol.Stem Cell Reports j Vol. 11 j 1391–1406 j December 11, 2018 1393
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Endothelial Phenotype of iPSC-Derived ECs
As a further demonstration of the quality of obtained ECs,
we proceeded in the analysis of specific markers. In partic-
ular, a specific gene expression profile was previously
described for blood endothelial cells (BECs) and lymphatic
endothelial cells (LECs) (Furuhata et al., 2007; Nelson et al.,
2007). Thus, we investigated whether these genes were
expressed by iPSC-derived ECs using HUVECs, BOECs,
HIMECs (human islet microvascular endothelial cells),
and HDLECs (human dermal LECs) as comparison. RT-
PCR analysis using BECs-specific markers (Figure 3A)
showed similar expression among iPSC-derived ECs,
BOECs, and HUVECs, while LEC-specific markers were
not expressed in differentiated ECs (Figure 3B), demon-
strating that iPSC-derived ECs acquired the phenotype of
microvascular ECs with our new optimized differentiation
protocol. Previous works demonstrated that ECs of
different origin can express F8 at different levels (Pan
et al., 2016). We were able to obtain higher levels of F8 at
the mRNA level in healthy iPSC-derived ECs through the
differentiation in BECs demonstrating that they are more
efficient, compared with LECs, in F8 expression in vitro
(Figure 3C).
Furthermore, we proved the acquired functionality of
ECs performing tubulogenesis assay, showing that ECs
were able to form complete and well-defined vessel-like
tubular structures when cultured in Matrigel (Figure 3D).
To further confirm terminal differentiation of the iPSC-
derived ECs, we transduced these cells with LVs carrying
GFP under the control of endothelial-specific promoters
FLK1, TIE-2, and VEC (LV.FLK1.GFP, LV.TIE-2.GFP, and
LV.VEC.GFP). The ubiquitous PGK promoter (LV.PGK.GFP)
was used as positive control, while hepatocyte- and
myeloid-specific promoters (TTR and CD11b) were used
as negative controls. Flow cytometry analyses showed
that 72% ± 6.5%, 61% ± 2.5%, and 50% ± 4%of transduced
cells were GFP+ under FLK1, TIE-2, and VEC promoters,
respectively, while only 3% ± 1.6% and 3% ± 1% were
GFP+ under TTR and CD11b promoters (Figure 3E). TheseFigure 1. Characterization of Healthy and Hemophilic CD34+-Der
Representative phase-contrast microscopy showing ESC-like morpholo
(C) CD34+ cell-derived iPSCs. Positivity for alkaline phosphatase stain
endogenous SC markers (OCT4, SOX2, and KLF4) on healthy (E) and HA
used as negative control and HEK293T cells transduced with the repro
at the protein level was detected by immunofluorescence in healthy (I
SSEA4 (green), TRA1-81 (red), and DAPI (blue). Scale bars, 100 mm
genetic analysis of healthy and HA CD34+-iPSCs demonstrated norm
methylated status in isolated CD34+ cells and unmethylated in iPSC
passages both in healthy and HA iPSCs (O and P, respectively). iPSC
markers of the three germ layers (Q): NES, NCAM, and OTX2 (ectode
(endoderm), and showed adipose (R), osteogenic (S), and chondroge
experiments. Scale bars, 100 mm.data proved that iPSC-derived ECs were bona fide ECs.
The differences in transgene (GFP) expression reflect the
heterogeneous populations obtained with the endothelial
differentiation protocol used. Indeed, KDR and TIE-2 are
early-stage ECmarkers of endothelial differentiation, while
VEC is a late-stage marker.
Finally, ECs were further transduced with an integrase
defective (ID)-LV carrying the Cre recombinase to excise
the reprogramming vector, thus avoiding reactivation
of the exogenous reprogramming factors in terminally
differentiated iPSC-derived ECs. The recombinase effi-
ciently excised the reprogramming LoxP-flanked LV
cassette, since the copy-number analysis revealed a
mean of 0.05 integrated copy/cell, while the parental EC
population contained 2.5 copies/cell (Table S3). In conclu-
sion, we demonstrated that Cre expression successfully
removed LV-exogenous reprogramming factors in differ-
entiated ECs incrementing the safety of the cells to be
used in vivo.
Hemophilic CD34+-iPSC-Expressing FVIII Can Be
Differentiated into ECs
Before endothelial differentiation, HA-CD34-iPSCs were
genetically corrected by LV.VEC.FVIII transduction (Fig-
ure S1C); LV.VEC.GFP served as control. EBs were gener-
ated from both FVIII- expressing and not expressing
(NE) HA-CD34+-iPSCs. Expressing and NE cells acquired
endothelial-like morphology and demonstrated endothe-
lial marker expression by RT-PCR (Figures 4A, S5A, and
S5B) and flow cytometry analyses (Figure 4B for NE and
4c for FVIII-expressing ECs). BOECs and fibroblasts were
used as positive and negative controls, respectively (Fig-
ure S4). IF staining revealed the expression of CD31 in
both corrected and NE ECs (Figures 4D and 4E, respec-
tively, and Figures S5C and S5D), highlighting their distri-
bution at cellular junction level and FVIII expression only
in FVIII-transduced cells (Figure 4E). Interestingly, von
Willebrand factor (VWF), an endothelial marker func-
tioning as FVIII carrier in the bloodstream, appearedived iPSCs
gy of both healthy (clone HD 1.5) (A) and hemophilic (clone HA 3.1)
ing of healthy (B) and HA iPSCs (D). Scale bars, 200 mm. RT-PCR for
(F) iPSCs. RT-PCR for exogenous factors (G and H). CD34+ cells were
gramming vector was used as positive control. SC marker expression
) and HA iPSCs (J). Markers used were: OCT4 (green), SOX2 (green),
. Data are representative of three independent experiments. Cyto-
al karyotypes (K and L, respectively). NANOG promoter was in a
s (M and N). Telomere length analysis showed an increase during
s, cultured in low adhesion plate, gave rise to EBs that expressed
rm), ACTA2, TBXT, and TBX6 (mesoderm), AFP, FOXA2, and SOX17
nic (T) potential. All data are representative of three independent
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Figure 2. Endothelial Differentiation of Healthy CD34+-Derived iPSCs, Clone HD 1.5
Representative phase-contrast microscopy showing the acquired endothelial morphology after 10 and 20 days of iPSC differentiated with
BMP4 (A) and VEGF protocols (B). RT-PCR for endothelial markers on ECs after 10 and 20 days of differentiation with the two different
protocols (C). Data are representative of three independent experiments. CD34+-derived iPSCs were used as negative control, HUVECs as
positive control. LSECs were used as positive control only for F8. Representative flow cytometry plot (D) revealing the acquired EC
phenotype of wild-type ECs at passage 8 post differentiation. The histogram overlays show the expression of different endothelial markers
(CD31, VEC, KDR, and VWF) and of CD45, used as negative marker. Non-labeled cells were used as negative control in each plot (black line).
Numbers are mean percentage ± SD of three independent experiments (n = 3). Telomere length analysis showed a progressive shortening in
differentiated cells at different passages (E). NANOG promoter returned to a methylated state in ECs (F). Cytogenetic analysis of healthy
endothelial cells (G). Scale bars, 200 mm.
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Figure 3. Markers for Endothelial Specification and Acquired Functionality of Healthy ECs, Clone HD 1.5
RT-PCR for endothelial markers specific for BECs on healthy ECs (A). RT-PCR for endothelial markers specific for LECs on healthy ECs.
HUVECs, BOECs, HIMECs, and HDLECs were used as positive controls, water was used as negative control (B). RT-PCR for F8 and VWF in
different endothelial cell types. ACTB correlates to the previous RT-PCR (C). Matrigel assay showing the ability of differentiated cells to
form tubules in vitro (D). Scale bars, 25 mm. ECs transduced with LV expressing GFP under the control of endothelial-specific promoters
FLK1, TIE2, and VEC (E). Dot plots are representative and numbers are mean percentage ± SD of three independent experiments.
Stem Cell Reports j Vol. 11 j 1391–1406 j December 11, 2018 1397
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during the differentiation process (Figures 4A–4C). As pre-
viously described for healthy ECs, telomere lengths and
NANOG methylation profile were analyzed and showed
the mature stage of differentiation reached by HA iPSC-
derived ECs (Figures 4F and 4G). Furthermore, FVIII-ex-
pressing ECs showed a stable karyotype (Figure 4H). We
performed in vitro tubulogenesis assay and VEC-FVIII-
ECs gave rise to a complex tubule network, like healthy
ECs (Figures 4I, S5E, and S5F).
Finally, to assess if FVIII was efficiently secreted, FVIII
antigen and activated partial thromboplastin time aPTT
assays were performed on the culture medium from
both FVIII-expressing and HA cells. Antigen assay
showed the secretion of 60 ± 3.4 ng/mL of FVIII by
FVIII-expressing cells; healthy iPSC-derived ECs were
used as positive control showing the secretion of 28 ±
2.9 ng/mL of FVIII, while FVIII was undetectable for
HA-ECs (Figure 4J). VEC-FVIII-EC-conditioned medium
displayed a shorter aPTT when compared with culture
medium from HA-ECs (Figure 4K). Collectively, these re-
sults demonstrate that genetically corrected HA-CD34-
iPSCs acquired the morphology, gene expression pattern,
and functionality of mature ECs.
Transplanted iPSC-Derived ECs Engraft and
Proliferate in the Mouse Liver
The FVIII expression and secretion was evaluated in vivo us-
ing a previously described mouse model of HA and LSEC
transplantation (Follenzi et al., 2008). To assess the feasi-
bility of this approach, we initially transplanted 2 3 106
healthy GFP+ iPSC-derived ECs into the liver of monocro-
taline (MCT)-conditioned NSG mice to evaluate their
engraftment and proliferation (n = 6). Cells engrafted in
liver parenchyma and proliferated up to 12 weeks after
transplantation, the longest time point analyzed (Fig-
ure 5A). The co-staining with human CD31 and the cell
morphology confirmed the endothelial phenotype of
transplanted cells (Figure 5A). Moreover, they formedFigure 4. Endothelial Differentiation of Hemophilic CD34+-Deriv
HA iPSCs were corrected with an LV.VEC-hBDDFVIII. LV.VEC-GFP was us
markers on FVIII-expressing and not expressing ECs (A). HA-CD34+
control. HEK293T cells transduced with VEC.FVIII were used as positiv
experiments. Representative FACS analysis of HA- (B) and FVIII-expres
overlays show the expression of different endothelial markers (CD31
labeled cells were used as negative control in each plot (black line). Nu
(n = 3). Immunofluorescence staining with CD31 (red), FVIII (green)
25 mm. Telomeres length showed a progressive shortening in different
methylated state in HA ECs (G). Cytogenetic analysis of VEC-FVIII-ex
formed tubule networks when cultured in Matrigel (I). Scale bars, 200
showed FVIII expression only by healthy and VEC.FVIII-transduced EC
VEC.FVIII and healthy ECs and not from HA-ECs (K). ***p < 0.001. (A
Average of three biological replicates (means ± SD) from clones HA 2vessel-like structures in the host liver demonstrating that
healthy iPSC-derived ECs were able to engraft and prolifer-
ate successfully in the mouse liver after transplantation.
In Vivo FVIII Expression and Correction of the
Hemophilic Phenotype after Transplantation of
Genetically Corrected iPSC-Derived ECs
To further evaluate FVIII secretion by FVIII-expressing cells,
we transplanted GFP+ VEC-FVIII- ECs in MCT-conditioned
NSG-HA mice (n = 8 each condition). The engraftment
was assessed by IF staining and flow cytometry analyses
12 weeks after GFP+ VEC-FVIII-ECs transplantation. Cells
proliferated and repopulated up to 30% of non-paren-
chymal cells (NPC) in recipient mice livers and were pre-
sent for up to 3 months (Figure 5B). The expression of
hCD31 confirmed the endothelial phenotype of trans-
planted cells (Figures 5B and 5C). No GFP+ hepatocytes
were detected (Figure S5A). Transplanted cells were
observed only in liver sections of transplanted mice and
were not detected in other organs such as spleen, kidney,
and lung, as shown by IF (Figure S6B). The absence of pos-
itive cells in these organs was also confirmed by PCR on
genomic DNA (gDNA) (Figure S6C). aPTT assay was per-
formed 3, 6, 9, and 12weeks after transplantation. The rela-
tive FVIII activity inmice transplanted with VEC-FVIII-ECs
was 3.36% ± 0.6% after 3 weeks, which increased to 4.51%
± 0.3% after 6 weeks, and remained stable at 9 and 12weeks
(5.21% ± 0.38% and 5.77% ± 0.52%, respectively), while
mice transplanted with uncorrected cells had no detectable
FVIII activity (Figure 5D). At 12 weeks, bleeding assay on
transplanted mice confirmed aPTT results. Indeed, mice
transplanted with HA-ECs did not show a therapeutic
correction, unlike the VEC-FVIII-EC-transplanted mice
(Figure 5E). Taken together, these results demonstrate
that the hemophilic phenotype can be rescued in HA
mice by transplantation of ECs derived from HA-iPSCs
and corrected by LVs carrying FVIII under the control of
the endothelial-specific VEC promoter.ed iPSCs, Clones HA 2.2, HA 3.1, and HA 4.9
ed as control of transduction. Representative RT-PCR for endothelial
-derived iPSCs were used as negative control, HUVECs as positive
e control only for F8. Data are representative of three independent
sing ECs (C) acquired at passage 7 and 8, respectively. The histogram
, VEC, KDR, and VWF) and of CD45, used as negative marker. Non-
mbers are mean percentage ± SD of three independent experiments
, and DAPI (blue) on HA ECs (D) and VEC.FVIII ECs (E). Scale bars,
iated cells at different passages (F). NANOG promoter returned to a
pressing ECs demonstrated a normal karyotype (H). VEC-FVIII-ECs
mm. VEC-FVIII ECs were able to secrete FVIII. FVIII antigen assay
s (J). aPTT analysis showed FVIII activity in culture media only from
and D–I) Data were obtained from clone HA 3.1. (B, C, J, and K)
.2, HA 3.1, and HA 4.9.
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Figure 5. Endothelial Transplantation by Portal Vein Injection of Healthy and Hemophilic CD34+-Derived ECs
(A–C) Healthy ECs (clone HD 1.5) were transplanted by portal vein injection in MCT-conditioned NSG mice (n = 6). Representative
immunofluorescence on liver sections showing the presence of the co-staining between GFP and hCD31 up to 12 weeks after trans-
plantation (A). FVIII-expressing and not expressing HA-ECs (clone HA 3.1) were transplanted in MCT-conditioned NSG-HA mice (n = 8 each
condition). Representative immunofluorescence on liver sections of mice transplanted with GFP+ -VEC-FVIII-ECs confirmed the co-staining
between GFP and hCD31 (B). Representative flow cytometry plots revealing the percentage of GFP+ and hCD31+ cells among liver NPCs (C).
aPTT on plasma of transplanted mice, performed from 3 to 12 weeks after transplantation, showing an increase in mice transplanted with
VEC-FVIII-ECs up to 5.64 ± 0.84 after 12 weeks. Untreated mouse was used as negative control.
(D and E) Mice transplanted with VEC-FVIII-ECs showed a decrease in bleeding volume (D) compared with HA-ECs transplanted mice (E)
(n = 8 each condition) (means ± SD) (**p < 0.01, ***p < 0.001). Scale bars, 50 mm.
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Figure 6. Intraperitoneal Implantation of Endothelial Cells with Cytodex Micro-Carrier Beads
GFP+-VEC-FVIII-ECs, HA-ECs (clone HA 3.1), and healthy ECs (clone HD 1.5) were injected intraperitoneally in NOD/SCID HA mice in
association with Cytodex micro-carrier beads (n = 4 each condition). aPTT performed 3 days, 7 days, and 3 weeks after injection showed
that LV-FVIII- corrected ECs restored FVIII activity (5.88% ± 1.5% on day 3; 6.0% ± 0.96% on day 7; 4.82% ± 0.14% after 3 weeks), more
than healthy ECs (3.24% ± 0.6% on day 3; 2.52% ± 0.6% on day 7; 1.28% ± 0.18% after 3 weeks) (means ± SD) (*p < 0.05) (A).
Representative immunofluorescence on beads showed the co staining of GFP and hCD31 confirming the endothelial phenotype of the
cells (B). PCR on gDNA for integration on recovered beads (C). LV.VEC.FVIII was used as positive control. Scale bar, 50 mm.Intraperitoneal Injection of iPSC-Derived ECs in a
Mouse Model of HA Secreted FVIII
Finally, we assessed whether ECs injected in the peritoneal
cavity can survive and secrete FVIII at therapeutic levels
when combined with microcarrier beads supporting their
viability, a safer therapeutic strategy than using MCT to
condition the recipient that has a tumorigenic potential.
Ten million GFP+ healthy iPSC-derived ECs, hemophilic
GFP+ ECs, and GFP+-VEC-FVIII-ECs were injected in
NSG-HA mice in association with microcarrier beads
(n = 4 each condition). Three days after transplantation
FVIII activity levels in mice receiving healthy iPSC-derived
ECs and VEC- FVIII-ECs were 3.24% ± 0.6% and 5.88% ±
1.5%, respectively, while in controls (beads only and HA
ECs) FVIII activity was undetectable (Figure 6A). One
week later, mice injected with healthy iPSC-derived ECs
showed 2.52% ± 0.6% FVIII activity, and VEC-FVIII-ECs
transplanted mice showed 6.0% ± 0.96% FVIII activity.
Three weeks after injection, FVIII activity levels in mice
receiving healthy iPSC-derived ECs and VEC-FVIII-ECs
were 1.28% ± 0.18% and 4.82% ± 0.14%, respectively (Fig-
ure 6A). These results demonstrate that VEC-FVIII-ECs were
able to secrete FVIII at therapeutic levels in vivo and athigher level than healthy iPSC-derived ECs. IF staining
and PCR on gDNA on recovered beads after 3 weeks
demonstrated that GFP+ cells were still associated to the
beads (Figures 6B and 6C). The co-staining of GFP and
hCD31 confirmed the presence and the endothelial pheno-
type of the transplanted cells. These findings suggest that
iPSC-derived ECs can survive and secrete functional FVIII
when injected into the peritoneal cavity associated to a
scaffold supporting their cell viability and functionality.DISCUSSION
New strategies for a definitive cure of HA are needed, and
gene and cell therapy could represent a powerful therapeu-
tic approach. Thus, the possible use of genetically corrected
autologous iPSCs is appealing. However, several issues need
to be solved, such as the identification of the best cell
source to be reprogrammed or the best cellular target to
use after iPSC differentiation. We generated iPSCs from
skin-derived fibroblasts and CD34+ cells of CB and PB.
The CD34+ cells gave rise to iPSCs earlier (approximately
3 weeks) compared with fibroblasts (2 months) in allStem Cell Reports j Vol. 11 j 1391–1406 j December 11, 2018 1401
reprogrammed samples. This observation highlighted that
the differentiation stage of the starting cells is critical for
the return to a pluripotent state (Eminli et al., 2009). We
identified CD34+ cells from PB as the safest and easiest-
to-access cell source to be reprogrammed in HA patients
compared with skin biopsy. The iPSCs can be derived
through several strategies and by several factors. For safety
concerns, we generated iPSCs omitting c-Myc, therefore re-
sulting in a reduced reprogramming efficiency (Nakagawa
et al., 2008). By including the miRNAs302/367 into LoxP-
flanked LVs carrying OCT4, SOX2, and KLF4 we generated
iPSCs from PB CD34+ cells in a time range and efficiency
comparable with a reported study using all four factors
(Merling et al., 2013). This is due to the interplay between
miRNAs302/367 clusters andOCT4 and SOX2 in the induc-
tion and maintenance of pluripotency (Card et al., 2008).
We demonstrated that the LVexpression cassette was spon-
taneously silenced in established iPSC clones. However, the
integrative nature of LVs required the excision of trans-
genes after reprogramming to avoid the reactivation of
exogenous factors that could increase iPSC oncogenic po-
tential and interfere with the differentiation and mainte-
nance of the differentiated state (Chakraborty et al.,
2013). Hence, we used Cre recombinase carried by an
IDLV to remove the LoxP-flanked reprogramming cassette
in ECs thus allowing the maintenance of the acquired
phenotype for over 30 passages. While successful, this
proof-of-concept study could be improved in the future
in terms of efficacy and safety by applying state-of-the art
methods for cell reprogramming. For instance, the stable
integration approach can be substituted by an efficient
non-integrating method such as Sendai virus vectors (Fu-
saki et al., 2009).
It is well known that liver is the main organ producing
FVIII. In particular, among the liver cell types LSECs are
the main source of FVIII (Everett et al., 2014; Fahs et al.,
2014; Shahani et al., 2014), and LSEC transplantation in
the liver of HA mice can correct the bleeding phenotype
(Follenzi et al., 2008; Kumaran et al., 2005). In 2009, endo-
thelial progenitors were generated from murine iPSCs and
were able to correct the HA phenotype when injected
into the liver parenchyma (Xu et al., 2009). Moreover,
Park et al. (2014, 2015) created model cell lines by using
TALEN or CRISPR-Cas9 technology to invert/revert a big
portion of the chromosomal segment that spans the
portion of F8 gene in iPSCs. ECs obtained from the inver-
sion-corrected iPSCs expressed F8 and were able to rescue
the phenotype in short-term experiments when injected
in HA mice (Park et al., 2015).
In the present investigation, we differentiated iPSCs
into ECs using two different protocols enlightening the
endothelial differentiation efficiency. The improved dif-
ferentiation protocol involving BMP4, besides VEGF,1402 Stem Cell Reports j Vol. 11 j 1391–1406 j December 11, 2018pushed cells through a mesoderm transition before defin-
itive endothelial differentiation, allowing the formation
of functional and stable microvascular endothelial cells
able to secrete FVIII for long term. These ECs acquired
an endothelial gene expression pattern specific for blood
endothelial markers more than lymphatic endothelial
markers. Obtaining ECs from iPSCs with this protocol
could be useful for disease modeling, cell therapy, and tis-
sue engineering applications in which it is important to
obtain high amounts of ECs. For HA cell therapy, we
successfully corrected ECs by LV expressing a functional
form of FVIII under the control of the endothelial-specific
VEC (cadherin 5) promoter. The use of the VEC promoter
allowed us to restrict FVIII expression in the desired
cell type and to assess that iPSC-derived differentiated
cells were effectively ECs (Merlin et al., 2017). In fact,
following differentiation, ECs were able to express and
secrete FVIII after genetic correction, demonstrating the
transcriptional activation of the endothelial-specific pro-
moter in vitro and in vivo. The iPSC-derived ECs trans-
planted into the liver of MCT-conditioned NSG-HA mice
repopulated the parenchyma, forming new vessels ex-
pressing hCD31. More importantly, EC transplantation
rescued the hemophilic phenotype both in the short
and long term, resulting in up to 6% FVIII activity. We
demonstrated that iPSC-derived ECs expressed the FVIII
protein effectively, engrafted within the hepatic paren-
chyma, and provided the phenotypic correction of HA
mice. Envisioning clinical application of EC transplanta-
tion into the liver, it would be important to select the
right drug because it should not be detrimental for the
recipient while selectively damaging the hepatic endothe-
lium to improve EC engraftment and proliferation.
Importantly, ECs restored FVIII activity not only when
transplanted directly into the liver but also when intraper-
itoneally injected in association with micro-carrier beads.
This result is exciting from a basic and translational
perspective. As basic perspective, it is crucial to obtain hu-
man ECs that could engraft in a mouse generating a
chimeric liver in which it would be possible to study the
endothelial functions during cell-cell interactions in a
controlled environment during liver repopulation. Ideally,
as a translational outlook, this strategy can be effective
because ex-vivo corrected cells need to be expandedwithout
losing transgene expression and to be embedded into a
medical device. While confining and protecting trans-
planted cells into desired anatomical sites, this structure
allows the release of the therapeutic product over time.
Such an approach could be translated in children, where
direct gene therapy is still a concern for the hemophilia
community.
Moreover, to overcome safety issues related to LVrandom
integration, it would be better to rely on the use of AAV- or
LV-mediated genome-editing strategies to introduce the
FVIII coding sequence into putative safe harbor loci, such
as AAVS1 or CCR5 (Oceguera-Yanez et al., 2016; Sebastiano
et al., 2014; Wallen et al., 2015).
At present, a phase I clinical trial for type 1 diabetes is
ongoing in which pancreatic progenitor cells are encap-
sulated in a device, which prevents immunoreactions
(http://www.eurostemcell.org/commentanalysis/making-
insulin-producing-beta-cells-stem-cells-how-close-are-we).
Further, it has recently been published that macro-encap-
sulation devices loaded with neonatal pancreatic tissue
and transplanted into RIP-LCMV.GP mice prevented dis-
ease onset in a model of virus-induced diabetes mellitus
(Boettler et al., 2016). As such, the prospect of placing
FVIII-secreting ECs into a device or scaffold is feasible and
clinically attractive for future therapeutic approaches to pa-
tients affected with HA and other diseases.EXPERIMENTAL PROCEDURES
CD34+ Cell Purification and Culture
Non-mobilized PB was collected from seven healthy donors, and
one heterozygous donor, and four patients. The study for the use
of samples of human origin was approved by the Ethical Commit-
tee of Novara, Italy. MNCswere purified by gradient centrifugation
on Ficoll (GE Healthcare) and CD34+ cells were isolated using the
MACS CD34+ MicroBeadKit (Miltenyi Biotec) according to the
manufacturer’s protocol. Isolated cells were cultured for 4 days in
HPGM medium (Lonza) supplemented with 1% human serum al-
bumin (Sigma-Aldrich), 50 ng/mL of hSCF, hFlt3-ligand, hTPO,
and hIL-3 (Immunotools).
Vector Transduction for Reprogramming and FVIII
Correction
Five days after isolation, both healthy and hemophilic CD34+
cells from PB and CB and fibroblasts from skin biopsies were
transduced with LV.SFFV.OSK and an additional Cre-excisable
polycistronic LV carrying miRNA cluster 302\367 followed by
OSK cassette (LV.SFFV.miR- 302\367.OSK) by a single spinocula-
tion at MOI = 5–10 at 300 g for 1 hr. Two days later, the cells
were seeded on a human foreskin fibroblast (HFF) feeder layer
in HPGM, medium was replaced with HES medium after 2 days.
Individual iPSCs colonies were passaged by mechanical dissocia-
tion. HA-CD34+-derived iPSCs were genetically corrected by an
LV carrying the hBDD.FVIII under the control of endothelial-spe-
cific VEC promoter (LV.VEC.hBDDFVIII). LV.VEC.GFP was used as
a control.
iPSC Culture and EB Generation
iPSCs were cultured and characterized using standard techniques
on irradiatedHFFs in HESmedium (Okada et al., 2010). For EB gen-
eration, iPSCs were disintegrated mechanically and plated onto
low attachment plates for 5 days in HPGM. Then EBs were used
for ECs differentiation and adipogenic, osteogenic and chondro-
genic differentiation.Endothelial Cell Differentiation
For endothelial differentiation, EBs were generated and differenti-
ated in ECs using two different protocols the VEGF protocol and
the BMP4 protocol. For the VEGF protocol, formed EBs were
directly plated on 0.1% gelatin-coated six-well plates in KO-
DMEM+10% FBS (ECmedium) with 50 ng/mL of VEGF (Immuno-
tools) for 20 days. For the BMP4 protocol, EBs were grown for
2 days in EC medium alone, on day 4 BMP4 (Immunotools) was
added (20 ng/mL). On day 6, EBs were cultured in EC medium
with 20 ng/mL of basic FGF and 20 ng/mL of BMP4. On day 8
EBs were plated on 0.1% gelatin-coated six-well plates in EC me-
dium with 20 ng/mL bFGF and 50 ng/mL of VEGF. At day 10,
medium containing only 50 ng/mL of VEGF was added and main-
tained until day 20. Cells were maintained in EC medium with
50 ng/mL of VEGF for up to 25–30 passages.
LV Transduction of ECs
ECswere transduced with LVs containingGFP under the control of
endothelial-specific promoters TIE-2, VEC, and FLK1. As a positive
control, LVs expressing GFP under the ubiquitous PGK promoter
was used. As a negative control, LVs expressing GFP under hep-
ato-(TTR) and myeloid-specific (CD11b) promoters were used. All
LVs were used at MOI = 10 (around 106 TU/ml).
Animals and Procedures
Animal studies were approved by the Animal Care and Use Com-
mittee of the Universita` del Piemonte Orientale ‘‘A.Avogadro’’
(Novara, Italy). Hemophilic NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG-
HA) mice, generated in our laboratory (Zanolini et al., 2015), at
6–8 weeks of age, were used for cell transplantation studies.
Animals received 200 mg/kg MCT (Sigma-Aldrich) in saline intra-
peritoneally 24hr prior to intraportal transplantation. To blunt im-
mune responses against GFP transgene reporter, mice were given
30 mg/kg cyclophosphamide (Cytoxan; Bristol-Myers Squibb) in
normal saline intraperitoneally twice a week for the duration of
the study, starting from the day prior to surgery. Mice were anes-
thetized with isoflurane. For cell transplantation, 2 3 106 ECs in
0.3 mL serum-free DMEM were injected into the portal vein, as
described previously (Follenzi et al., 2008). Controls received
serum-free medium.
For bead transplantation, cells were mixed with Cytodex
3 microcarrier beads (Amersham Pharmacia Biotech) in a ratio
of 107 cells/mL of rehydrated microcarriers and injected
intraperitoneally.
FVIII Activity and FVIII Antigen Assay
Plasma samples of transplanted mice and supernatants of uncor-
rected and LV-VEC-hBDDFVIII–corrected ECs were analyzed for
FVIII activity by aPTT. Standard curves were generated by serial
dilution of recombinant human BDD FVIII (ReFacto) starting
from 1 U/mL (100%) in hemophilic mouse plasma for aPTT assay.
Results were expressed in percentage of correction. FVIII antigen in
supernatant of cultured uncorrected and LV-VEC-hBDDFVIII-cor-
rected ECs was quantified by ELISA sandwich using the Matched-
Pair Antibody Set for ELISA of human Factor VIII antigen (Affinity
Biologicals) following the manufacturer’s protocol. Standard
curves were generated by serially diluting ReFacto in cultureStem Cell Reports j Vol. 11 j 1391–1406 j December 11, 2018 1403
medium and results were expressed as ng/mL. For bleeding assay
methods see Supplemental Experimental Procedures.
Statistical Analysis
All data were expressed as mean ± SD. Graphs were generated, and
statistical analysis was performed with Prism 5 (Graph Pad). The
p valueswere calculatedusing Student’s t testwith two-tailed distri-
bution, assuming equal standard deviation distribution, one-way
ANOVAwith Bonferroni post-hoc test; p < 0.05 values were consid-
ered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001.
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